Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial.
Jongbeom ShinJung Hwan LeeSoo-Hyun ParkBoram ChaKye Sook KwonHyungkil KimYong Woon ShinPublished in: Biomedicines (2022)
Fecal microbiota transplantation (FMT) could decolonize multidrug-resistant organisms. We investigated FMT effectiveness and safety in the eradication of carbapenem-resistant Enterobacteriaceae (CRE) and vancomycin-resistant enterococci (VRE) intestinal colonization. A prospective non-randomized comparative study was performed with 48 patients. FMT material (60 g) was obtained from a healthy donor, frozen, and administered via endoscopy. The primary endpoint was 1-month decolonization, and secondary endpoints were 3-month decolonization and adverse events. Microbiota analysis of fecal samples was performed using 16S rRNA sequencing. Intention-to-treat analysis revealed overall negative conversion between the FMT and control groups at 1 (26% vs. 10%, p = 0.264) and 3 (52% vs. 24%, p = 0.049) months. The 1-month and 3-month CRE clearance did not differ significantly by group (36% vs. 10%, p = 0.341; and 71% vs. 30%, p = 0.095, respectively). Among patients with VRE, FMT was ineffective for 1-month or 3-month negative conversion (13% vs. 9%, p > 0.999; and 36% vs. 18%, p = 0.658, respectively) However, cumulative overall negative-conversion rate was significantly higher in the FMT group ( p = 0.037). Enterococcus abundance in patients with VRE significantly decreased following FMT. FMT may be effective at decolonizing multidrug-resistant organisms in the intestinal tract.
Keyphrases
- multidrug resistant
- gram negative
- drug resistant
- acinetobacter baumannii
- klebsiella pneumoniae
- end stage renal disease
- ejection fraction
- study protocol
- double blind
- randomized controlled trial
- peritoneal dialysis
- phase ii
- open label
- methicillin resistant staphylococcus aureus
- pseudomonas aeruginosa
- stem cells
- cystic fibrosis
- cell therapy
- placebo controlled
- microbial community
- patient reported
- small bowel